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Toronto, Ontario, Canada
Objectives We sought to determine whether infants (younger than 1 year old) had similar clinical benefits with individual-
ized anticoagulation management as older children and adult undergoing cardiopulmonary bypass (CPB).
Background Individualized heparin and protamine management in older children and adults undergoing CPB has been asso-
ciated with improved clinical outcomes.
Methods Ninety infants younger than 1 year of age undergoing CPB were enrolled in a randomized, controlled trial com-
paring weight-based anticoagulation management using activated clotting time (ACT) to individualized manage-
ment with Hemostasis Management System Plus. Manufacturer’s guidelines were followed for the first 33 pa-
tients. A modified protocol was used for the last 57 patients with adjustments for coagulation system
immaturity and hemodilution on CPB.
Results The hemostasis management system (HMS) device consistently underestimated plasma anti-Xa levels, leading
to an overestimated required heparin dose. After a blinded interim analysis revealed poor outcomes in the ex-
perimental HMS group using manufacturer guidelines, the safety committee suspended the study pending proto-
col modifications. The use of the HMS device following the modified protocol resulted in more stable anti-Xa lev-
els during CPB with improved post-operative outcomes including reduced need for transfusions (71 ml/kg vs. 80
ml/kg; p  0.003), ventilation time (33 h vs. 49 h; p  0.04), intensive care (88 h vs. 99 h; p  0.003), and
hospital length of stay (192 h vs. 216 h; p  0.001), compared with the weight-based protocol.
Conclusions This study supports the use of the HMS device, with a modified protocol for infants younger than 1 year of age,
for anticoagulation management during CPB. Clinical guidelines for the use of the HMS device should be modi-
fied for infants younger than 1 year of age. (J Am Coll Cardiol 2010;56:1794–802) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.046h
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Cnfants undergoing cardiopulmonary bypass (CPB) for car-
iac surgery experience higher surgical morbidity and mor-
ality compared with older children and adults (1). Increased
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edtronic. All other authors have reported that they have no relationships to disclose.o
Manuscript received January 7, 2010; revised manuscript received May 5, 2010,
ccepted June 6, 2010.emodilution, activation of the coagulation system, stimu-
ation of the inflammatory response, and hemostatic de-
angements in young children lead to thrombotic compli-
ations, bleeding, and more blood transfusions in the
erioperative period (1–6). The immaturity of the hemo-
tatic system in infants prevents adequate anticoagulation
uring CPB due to inherent deficiencies in antithrombin
AT) as well as other coagulation proteins. This results in
esistance to anticoagulation with heparin and ineffective
uppression of thrombin generation (7–9). Unfractionated
eparin is most commonly used for anticoagulation during
PB for cardiac surgery, not only to prevent gross clotting
f the bypass circuit but also to prevent more subtle
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November 23, 2010:1794–802 Anticoagulation in Infant Heart Surgeryctivation and consumption of coagulation system compo-
ents. Despite the large doses of heparin used during CPB,
xcessive thrombin and plasmin generation still occurs and
s associated with bleeding, thrombosis, and organ dysfunc-
ion post-operatively (10 –12). Current anticoagulation
ractices in children have been extrapolated from adult proto-
ols and are generally based on an empirical weight-based
eparin and protamine dosing regimen using an automated
hole blood activated clotting time (ACT) device to monitor
nticoagulation. There has been very little validation of any of
hese protocols in young children (13–19).
Individualized heparin and protamine management using
whole blood hemostasis management system (HMS) in
lder children and adults undergoing CPB has been asso-
iated with improved clinical outcomes. Studies have shown
ignificant reductions in thrombin generation during CPB
esulting in reduced post-operative bleeding and decreased
eed for blood transfusions (20–24) using this regimen. We
ought to determine whether using this method of managing
nd monitoring anticoagulation during CPB in infants
ounger than 1 year of age was associated with similar
mprovements.
ethods
tudy design. This randomized, controlled clinical study
as conducted after receiving institutional research ethics
oard approval at The Hospital for Sick Children, Toronto,
ntario, Canada. Written informed consent was obtained
rom the legal guardian of each patient before randomiza-
ion. The study began in August 2006 and was temporarily
uspended in June 2007 (HMS I: first study group of 33
atients) by the study’s independent data safety committee.
blinded interim analysis revealed poor outcomes in the
MS group and study-related adverse events. The original
rotocol was revised to limit the heparin dose recommended
y the HMS system. The research ethics board granted
pproval for the amended protocol, and the study resumed
n October 2007 (HMS II: second study group of 57
atients). Enrollment was completed in February 2009.
Patients were eligible for inclusion if they were younger
han 1 year of age at the time of elective surgery. Exclusion
riteria included patients weighing 2.0 kg, prematurity
36 weeks of age), preoperative use of anticoagulants at a
herapeutic dose, known history of bleeding or thrombotic
isorders, renal and/or liver failure, and AT replacement
herapy before surgery. Randomization was stratified by
ge (birth to 1 month and 1 month to 12 months); subjects
ere randomized in random blocks of 2, 4, and 6 using a
andom-number generator. Surgeons, anesthesiologists, and
ardiac critical care unit (CCCU) staff were blinded to each
atient’s group randomization, whereas the perfusionists
ere not blinded in order to administer the study interven-
ion. All study outcomes were assessed by trained personal
naware of the patient treatment assignment. heparin concentration mea-
urement. The HMS Plus He-
ostasis Management System
Medtronic Inc., Minneapolis,
innesota) is an automated pro-
amine titration method of antico-
gulation management. It pro-
ides both whole blood heparin
oncentration measurements and
CT (24–29). The principle of
MS management is based on
he heparin dose-response test
hat measures the in vitro antico-
gulation response of the pa-
ient’s blood to a known concen-
ration of heparin and calculates
he estimated heparin dose re-
uired to achieve the desired tar-
et heparin concentration. This
esponse is used to determine the whole blood heparin
oncentration necessary to achieve and maintain adequate
nticoagulation during CPB. The concentration of circulat-
ng heparin is monitored during CPB using the heparin
rotamine titration test. Each channel of the heparin
rotamine titration test cartridge contains a known quantity
f protamine with a constant amount of thromboplastin for
ctivation of the blood. The channel that most closely
eutralizes the heparin in the sample will be the first to clot.
n this channel, the protamine-to-heparin ratio is nearest to
he neutralization point (29). The heparin concentration is
lso used to calculate the protamine dose required for
eutralization of heparin after CPB.
eparin and protamine management. All heparin and
rotamine doses given by anesthesia were drawn up and
hecked by 2 perfusionists for safety and to maintain
linding. Empirical weight-based heparin and protamine
anagement was used for patients in the control group. The
CT (ACT Plus, Medtronic Inc.) was used to guide
eparin requirements before and during bypass. The HMS
as used for heparin and protamine management for
atients randomized to the treatment group. The decision to
dminister the total dose (patient  pump) of protamine as
alculated by the HMS was supported by literature describing
n increase in heparin concentration after modified ultrafiltra-
ion (30). The observation of residual laboratory plasma
nti-Xa levels after the protocol in the HMS I group prompted
further increase in the calculated protamine dose by a factor
f 1.5 subsequently used in the HMS II group. This was
equired to fully reverse residual heparin after CPB. Specific
etails regarding these protocols are shown in Table 1.
lood transfusion protocol. Blood transfusion protocol
as standardized throughout the study. Packed red blood
ells (PRBCs) were added to the prime to achieve and
aintain patient hematocrit at 28% to 30% during CPB.
or cyanotic patients, PRBCs were given to increase the
Abbreviations
and Acronyms
ACT  activated clotting
time
AT  antithrombin
CCCU  cardiac critical
care unit
CPB  cardiopulmonary
bypass
F1.2  prothrombin
fragments 1  2
HMS  hemostasis
management system
PRBCs  packed red blood
cells
TAT  thrombin-
antithrombinematocrit 33% to 35% before CPB termination. All
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Anticoagulation in Infant Heart Surgery November 23, 2010:1794–802atients received one-half unit of frozen plasma and one-
alf unit of platelets in the prime, with the remainder was
iven before removal of the cross-clamp. After CPB and in
he CCCU, patients received 10 ml/kg of platelets if the
latelet count decreased to 100,000/mm3 or if bleeding was
20 ml/kg/h. Patients were given cryoprecipitate (1 U/10 kg)
f fibrinogen was 1.0 g/l. Finally, in the post-operative
eriod, PRBCs were given as necessary to maintain a hemat-
crit of 28% for noncyanotic patients, 35% to 40% for
yanotic patients or if patients had clinical evidence of low
ardiac output including an arterial-mixed venous saturation
ifference 40, lactic acid 4 mmol/l, or poor ventricular
unction by echocardiogram (ejection fraction 40%). All
atients underwent modified ultrafiltration for 15 to 20 min
fter CPB.
ata collection. Arterial blood samples were obtained for
ll patients immediately after placement of the arterial line,
fter the pre-CPB heparin loading dose, 10 min after
nitiation of CPB, every 30 min during and at the termina-
ion of CPB, at 5 and 45 min after protamine administra-
ion, and on arrival and after 24 h in the CCCU. The
eparin dose response was determined on the sample
btained on arterial line insertion. Blood samples were
nalyzed for biochemistry, heparin protamine titration,
omplete blood count, and anti-Xa at all time points.
ibrinogen, D-dimers, AT, thrombin–AT (TAT) com-
lexes, and prothrombin fragments 1 and 2 (F1.2) were
easured after arterial line insertion, at initiation and
ermination of CPB, at 5 and 45 min after protamine
dministration, on arrival and after 24 h in the CCCU.
AT complex and F1.2 measurements were used to quan-
ify thrombin generation throughout CPB. The measure-
ents were performed using Enzygnost TAT complex and
1.2 (monoclonal) (Dade Behring, Marburg, Germany)
ssays. Total blood loss was estimated by measuring chest
ube losses during the first 24 h after CCCU admission.
lood transfusion requirements intraoperatively and for
eparin and Protamine Management During CPB for Both HMS I anTable 1 Heparin and Protamine Management During CPB for B
HMS I
Control Treatment
<1 Month
of Age
1 Month to
1 Year of Age
<1 Month
of Age
1 Month to
1 Year of Age
<1
of
Prime heparin 2 U/ml prime solution Based on HDR 4 U/ml pr
Anesthesia 400 U/kg 300 U/kg HDR (6.1 U/ml limit) 400
CPB heparin 150 U/kg, ACT 400 s
100 U/kg, ACT 400–480 s
Per HMS HPT
Protamine 4 mg/kg 3 mg/kg Per HMS HPT, total
(patient  pump)
protamine dose
4 m
Between HMS I and HMS II, the standard of care for heparin dosing in the prime for pediatric car
study-related change.
ACT  activated clotting time; CPB  cardiopulmonary bypass; HDR  heparin dose response;4 h post-operatively were tabulated by the total volume per catient weight and the type and number of blood product
nits transfused. Inotropic support score was calculated
very 6 h after CCCU arrival up to 24 h after arrival by
eans of the following formula, using drug doses expressed
s g/kg/min: dopamine  dobutamine  (epinephrine 
00)  (milrinone  10) (31). Total ventilation hours,
CCU and hospital length of stay, and intravascular throm-
osis until hospital discharge were also recorded.
tatistical analysis. Data are given as frequencies, medians
ith ranges and means with SDs as appropriate. Baseline
haracteristics and outcomes between study groups were com-
ared with the Fisher exact test, chi-square test, Wilcoxon
onparametric test, and Student t test as appropriate. Com-
arisons of outcomes were performed in multivariable lo-
istic or linear regression models adjusted for age at surgery,
urgeon, and surgery Aristotle score. All regression models
sed maximum likelihood methodology for parameter esti-
ation. Separate linear regression models adjusted as pre-
iously described were created for each laboratory test at
very time point. Data from both protocols were analyzed
eparately. The following variables were log-transformed in
inear regression models (descriptive statistics throughout
his paper remained from the nontransformed distribution):
eparin and protamine doses, transfusion volumes, time to
hest closure, chest tube volume loss, duration of ventilation
nd hospitalization, platelet count, TAT complex, and F1.2.
ll analyses were performed using SAS statistical software
ersion 9.1 (SAS Institute, Inc., Cary, North Carolina).
esults
nrollment and demographics. A total of 90 patients
ere enrolled, 33 in the original protocol (HMS I group)
nd 57 in the modified protocol (HMS II group). In the
MS I protocol, 16 of 33 patients (48%) were randomized
o the treatment arm compared with 28 of 57 patients (49%)
andomized to the treatment arm with the HMS II proto-
ProtocolsMS I and II Protocols
HMS II
Control Treatment
1 Month to
1 Year of Age <1 Month of Age
1 Month to
1 Year of Age
lution* 3 U/ml prime solution* 4 U/ml prime solution* 3 U/ml prime solution*
300 U/kg Adjusted heparin
concentration to
4.0 U/ml
Adjusted heparin
concentration to
3.5 U/ml
U/kg, ACT 400 s
/kg, ACT 400–480 s
Pre HMS, to maintain HPT at 3.0 U/ml
(max dose 1,500 U/kg, 1 month,
900 U/kg 1 month to 1 yr)
3 mg/kg Per HMS HPT, total (patient  pump) protamine
dose  1.5
rgery was changed at our institution, as reflected by the higher prime heparin doses; this was not
hemostasis management system; HPT  heparin protamine titration.d IIoth H
Month
Age
ime so
U/kg
150
100 U
g/kg
diac suol. Baseline and surgical patient characteristics are detailed
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November 23, 2010:1794–802 Anticoagulation in Infant Heart Surgeryn Table 2 and were comparable between the treatment and
ontrol groups for both protocols.
linical outcomes of the HMS I protocol. The HMS
evice was found to underestimate actual laboratory plasma
emographics and Surgical CharacteristicsTable 2 Demographics and Surgical Characteristics
HMS I (n 
Control (n  17) HMS
Demographic and clinical
Sex (male) 11 (65) 8 (5
Age at surgery, days 163 (6–262) 65 (2
Age 1 month at surgery 7 (41) 8 (5
Weight at surgery, kg 5.2 1.9 5.1
Diagnosis/surgical category
Septal defects 1 (6) 6 (3
Pulmonary venous anomalies 0 (0) 0 (0
TOF/DORV/PAVSD 9 (53) 3 (1
Single ventricle (stage I) 0 (0) 2 (1
Single ventricle (stage II) 1 (6) 1 (6
Transposition of great arteries 6 (35) 4 (2
Thoracic vein and arteries abnormalities 0 (0) 0 (0
Surgical
Aristotle score 9.5 (7.5–11.0) 9.0 (7
Aristotle category 4 (score 9.9) 8 (47) 7 (4
Surgeon
A 12 (71) 4 (2
B 5 (29) 11 (6
C 0 (0) 1 (6
D 0 (0) 0 (0
Perioperative
Cardiopulmonary bypass time, min 112 40 116
Cross-clamp time, min 69 19 67
Deep hypothermic circulatory arrest 0 (0) 2 (6
Selective cerebral perfusion —
Aprotinin 6 (35) 7 (4
Tranexamic acid 11 (65) 9 (5
Steroids given in operating room 5 (29) 7 (4
Vasopressin 0 (0) 3 (1
alues are n (%), mean  SD, or mean (range).
DORV  double outlet right ventricle; HMS  hemostasis management system; PAVSD  pulm
eparin and Protamine ManagementTable 3 Heparin and Protamine Management
HMS I (n 
Control (n  17) HMS
Slope of heparin dose response 86 25 90
Baseline heparin concentration, U/kg 4.5 1.6 4.4
Initial heparin dose, anesthesia, U/kg 395 (297–416) 324 (2
Initial heparin dose, prime, U/kg 222 (125–420) 451 (1
Additional heparin given before CPB, U/kg 99 (0–156) 102 (0
Heparin given on CPB, U/kg 105 (0–482) 574 (0
Total heparin dose, U/kg 739 (452–1,050) 1448 (6
Total protamine dose, U/kg 391 (297–505) 701 (2
Ratio protamine dose to initial heparin dose,
anesthesia, U/Kg
1.00 (0.95–1.27) 1.99 (0
Ratio protamine dose to total heparin dose,
U/kg
0.50 (0.29–0.71) 0.51 (0alues are mean  SD or mean (range).
Abbreviations as in Table 1.nti-Xa levels in infants. This caused an overestimated
equired dose of heparin (Table 3). The result was signifi-
antly poorer clinical outcomes including greater chest tube
olume loss (Table 4), transfusion requirement (Table 5),
HMS II (n  57)
6) p Value Control (n  29) HMS (n  28) p Value
0.50 14 (48) 18 (64) 0.29
0.001 96 (5–238) 120 (5–280) 0.02
0.74 10 (34) 11 (39) 0.61
0.89 4.7 1.3 5.2 1.8 0.27
0.04 8 (28) 4 (14) 0.33
1.00 3 (10) 0 (0) 0.24
0.04 6 (21) 9 (32) 0.38
0.23 3 (10) 1 (4) 0.62
1.00 0 (0) 1 (4) 0.50
0.71 7 (24) 8 (29) 0.77
1.00 2 (7) 5 (18) 0.25
.5) 0.59 9.0 (6.0–14.5) 9.5 (6.0–14.5) 0.94
1.00 12 (41) 14 (50) 0.60
0.02 10 (34) 14 (50) 0.29
0.04 6 (21) 5 (18) 1.00
0.49 4 (14) 1 (4) 0.36
1.00 9 (31) 8 (29) 1.00
0.75 105 40 106 38 0.55
0.85 76 33 73 31 0.24
0.17 4 (14) 5 (18) 0.73
— 5 (17) 5 (18) 1.00
0.73 1 (3) 0 (0) 1.00
0.73 28 (97) 28 (100) 1.00
0.49 12 (41) 10 (36) 0.79
0.11 5 (17) 4 (14) 1.00
tresia with ventricular septal defect; TOF  tetralogy of Fallot.
HMS II (n  57)
6) p Value Control (n  29) HMS (n  28) p Value
0.42 95 30 93 29 0.75
0.83 4.1 1.8 4.1 1.4 0.91
0) 0.005 316 (294–427) 304 (225–519) 0.001
50) 0.001 320 (199–645) 291 (160–846) 0.30
0.001 0 (0–213) 54 (0–206) 0.02
8) 0.001 75 (0–303) 272 (48–772) 0.001
205) 0.001 810 (521–1,355) 927 (667–1,593) 0.001
333) 0.001 404 (286–762) 666 (185–1,385) 0.001
.13) 0.02 1.11 (0.94–1.79) 2.19 (0.79–3.21) 0.005
.47) 0.88 0.50 (0.30–0.98) 0.72 (0.28–1.08) 0.3933)
(n  1
0)
–367)
0)
 2.6
8)
)
9)
3)
)
5)
)
.0–14
4)
5)
9)
)
)
 39
 28
)
—
4)
6)
4)
9)33)
(n  1
 28
 1.7
31–60
77–14
–390)
–1,18
18–3,
85–1,
.95–5
.16–1
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Anticoagulation in Infant Heart Surgery November 23, 2010:1794–802ntravascular thrombosis along with greater ventilation time,
nd longer CCCU and hospital stay (Table 4).
linical outcomes of the HMS II protocol. In the HMS
I protocol, patients in the treatment arm received signifi-
antly more heparin and protamine (all p values 0.001)
han control patients during the perioperative period, but
uch less than those in the HMS I (Table 2). Patients in
linical Outcomes (p Values From Models Adjusted for Age at SurgTable 4 Clinical Outcomes (p Values From Models Adjusted for
HMS (n  3
Control (n  17) HMS (n
Chest closure
Time protamine to sternal closure, min* 58 (23–125) 49 (30
Sternum closed in OR 17 (100) 11 (69
Sternum reopened in CCCU 1 (6) 1 (6)
Thrombosis
Factor VIIa given in OR 0 (0) 3 (19
Vitamin K 2 (12) 2 (12
Intravascular clot 0 (0) 3 (19
Inotrope support
Inotropic score in OR 8.7 2.7 9.3
Inotropic score 4 h in CCCU 8.6 3.4 9.7
Inotropic score 12 h in CCCU 8.1 3.1 9.5
Inotropic score 24 h in CCCU 6.9 3.2 8.2
Bleeding, ml/kg
Chest tube loss 4 h CCCU 5.1 (2.7–57.2) 13.6 (2.5
Chest tube loss 24 h CCCU 18.1 (9.6–129.0) 28.1 (8.0
Hospitalization, h
Ventilation length 47 (5–144) 70 (5–5
CCCU length of stay 70 (27–384) 105 (20
Total length of stay 196 (114–916) 307 (11
Mortality
In-hospital mortality 0 (0) 1 (6)
Deceased at last follow-up 2 (12) 3 (19
alues are mean (range), n (%), or mean  SD. *Chest closure in OR only.
CCCU  cardiac critical care unit; HMS  hemostasis management system; OR  operating ro
lood Transfusions (p Values From Models Adjusted for Age at SurTable 5 Blood Transfusions (p Values From Models Adjusted fo
HMS I (n 
CTRL (n  17) HMS (n
PRBCs total in OR, ml/kg 86 (35–147) 85 (3
PRBCs CCCU, ml/kg 6 (0–112) 20 (0
PRBCs total, ml/kg 97 (37–205) 112 (4
Platelets total in OR, ml/kg 16 (0–46) 14 (1
Platelets CCCU, ml/kg 0 (0–54) 0 (0
Platelets total, ml/kg 18 (0–56) 19 (1
FFP and cryoprecipitate total, ml/kg 60 (30–124) 91 (2
All blood products total, ml/kg 169 (79–374) 238 (9
Total units transfused in OR 8 (3–12) 9 (4
5 U transfused in OR 13 (76) 12 (7
Total units transfused CCCU 0 (0–12) 2 (0
0 U transfused in CCCU 8 (47) 14 (8
Total units (range) transfused OR and CCCU 9 (3–17) 11 (5
7 U transfused OR and CCCU 13 (76) 12 (7alues are mean (range) or n (%). *Favoring HMS.
FFP  fresh frozen plasma; PRBC  packed red blood cell; other abbreviations as in Tables 1 and 4.he treatment group were more likely to receive periodic
oses of heparin throughout CPB, which was a rare occur-
ence in the control group. As a result, the plasma anti-Xa
oncentrations were more stable throughout CPB (Fig. 1).
statistically significant increase in the ratio of protamine
o pre-CPB heparin dose was observed in the treatment
roup versus the control (Table 3).
Surgery Aristotle Score, and Surgeon)at Surgery, Surgery Aristotle Score, and Surgeon)
HMS II (n  57)
) p Value Control (n  29) HMS (n  28) p Value
0.001 50 (13–144) 64 (20–110) 0.04
0.02 25 (86) 24 (86) 1.00
1.00 0 (0) 0 (0) 1.00
0.11 1 (3) 0 (0) 1.00
1.00 4 (14) 2 (7) 0.68
0.11 5 (17) 1 (4) 0.20
0.99 9.9 4.1 8.6 3.4 0.16
0.56 8.1 3.6 7.6 2.9 0.56
0.99 8.2 2.7 7.6 3.4 0.52
0.38 5.7 3.3 5.6 3.5 0.89
) 0.05 9.1 (3.0–23.3) 7.6 (1.1–43.2) 0.66
7) 0.001 21.9 (11.0–61.3) 21.5 (7.5–70.0) 0.34
0.001 49 (5–237) 33 (4–234) 0.04
0.001 99 (20–356) 88 (27–312) 0.003
0) 0.001 216 (97–692) 192 (97–2,376) 0.001
0.49 0 (0) 0 (0) 1.00
0.66 2 (7) 0 (0) 0.50
Surgery Aristotle Score, and Surgeon)at Surgery, Surgery Aristotle Score, and Surgeon)
HMS II (n  57)
) p Value CTRL (n  29) HMS (n  28) p Value
) 0.001 65 (40–224) 64 (32–167) 0.01*
0.06 10 (0–37) 0 (0–29) 0.05*
) 0.001 80 (49–224) 71 (32–186) 0.003*
0.001 20 (0–83) 17 (0–54) 0.09*
0.001 0 (0–10) 0 (0–20) 0.80
0.001 24 (0–93) 25 (0–54) 0.13*
) 0.001 61 (28–133) 49 (26–113) 0.64
) 0.001 157 (93–438) 153 (75–354) 0.006*
0.20 5 (3–9) 5 (1–8) 0.41
0.34 12 (41) 7 (25) 0.17
0.94 1 (0–3) 0 (0–8) 0.20
0.07 17 (59) 12 (43) 0.26
0.25 6 (3–9) 6 (1–12) 0.84
0.33 9 (31) 5 (18) 0.20ery,Age
3)
 16
–134)
)
)
)
)
4.5
4.3
3.9
4.2
–93.7
–162.
28)
–645)
7–3,48
)gery,r Age
33)
 16
7–434
–107)
6–465
–102)
–20)
–102)
4–297
4–865
–21)
5)
–6)
8)
–23)
5)
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reatment patients had significantly higher platelet
ounts measured at all time points throughout CPB,
ignificantly lower levels of TAT complexes measured on
rrival and at 24 h in the CCCU and significantly lower
evels of F1.2 consistently measured after protamine on
rrival and at 24 h in the CCCU (Fig. 1). There was no
Figure 1 Trends in Laboratory Measurements of Anticoagulatio
Red lines represent control patients and black lines represent patients monitored
SD. Time point with (*) represent statistically significant differences in individual l
geon. Platelet count, thrombin-antithrombin complex, and prothrombin fragments 1
only. AAR CCU  critical care unit arrival; ACT  activated clotting time; CPB IND
PST HEP  post-heparinization; PST PROT  5 min after protamine administration
bypass time 60 min; 24H CCU  24 h after critical care unit arrival; 90M CPB ignificant difference between groups in serial measure- aents of AT, fibrinogen, D-dimers, hemoglobin, or
ematocrit at any time point.
leeding and transfusions. There was no significant dif-
erence between groups in chest tube loss at both time
oints (4 and 24 h after CCCU arrival) (Table 4). However,
atients in the treatment group received significantly fewer
ransfusions in the operating room and over the first 24 h
telet Count, and Thrombin Generation
he hemostasis management system (HMS) device. Represented are mean and
egression models adjusted for age at surgery, surgery Aristotle score, and sur-
were log-transformed in regression models. Data presented for the HMS II group
ction of cardiopulmonary bypass; END CPB  end of cardiopulmonary bypass;
CPB  cardiopulmonary bypass time 30 min; 60M CPB  cardiopulmonary
ulmonary bypass time 90 min.n, Pla
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inear r
 2
 indu
; 30M
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Anticoagulation in Infant Heart Surgery November 23, 2010:1794–802ant reduction in the number of patients who received5 U
f blood in the operating room, any transfusions in the
CCU, and 7 U of blood overall (Table 5) in the
reatment group. This did not, however, reach statistical
ignificance.
orbidity and hospital stay. Patients in the treatment
roup had significantly shorter ventilation times and CCCU
nd hospital lengths of stay compared with the control
roup. Five control patients (17%) (including 1 patient who
eceived recombinant activating factor VII) had thrombosis
uring their hospital stay compared with 1 (4%) in the
reatment group. There were no significant differences in
notrope requirements or in-hospital mortality between
roups (Table 4).
iscussion
he application of medical knowledge from adult studies to
ediatric patients without further evaluation is a potentially
angerous yet all too common occurrence. In this study, we
ound that a technology shown to have benefits in older
hildren and adults could not be readily applied to infants.
he physiology of children younger than 1 year of age is
undamentally different, from both hematological and car-
iovascular perspectives. The use of a modified protocol for
he HMS device, taking these factors into account, is
ssociated with improved surgical outcomes for patients
ndergoing cardiac surgery. This study exemplifies the need
or medical devices, protocols, and drug dosing to be
ppropriately validated for use in young children.
Post-operative bleeding and the restoration of hemostasis
n infants are the result of interactions between many
echanisms. Disturbances of coagulation arise due to fac-
ors such as hemostatic system immaturity, hemodilution,
ystemic inflammation, prolonged bypass time, and the use
f deep hypothermic circulatory arrest as well as age-related
ifferences in responses to heparin (9). Children with
ongenital heart disease, particularly cyanotic polycythemic
hildren, have further derangements of both platelet func-
ion and coagulation proteins (6,32–37). The physiological
mpact of CPB during infant surgery exceeds that in adults.
here are few clinical studies that have investigated strate-
ies for anticoagulation and monitoring in infants or the
ubsequent effects on hemostasis and clinical outcomes.
There is well documented evidence that the ACT has
erious limitations as a monitor of heparin-induced antico-
gulation during CPB. ACT measurements are being af-
ected by many variables other than heparin such as he-
odilution and hypothermia, as well as decreased platelet
unction. It is an inadequate monitor of anticoagulation
17,24). The prolongation of the ACT during bypass may
ead to misinterpretation that adequate anticoagulation is
resent even when heparin levels may be inadequate. Most
mportantly, studies have shown poor correlation between
CT values and plasma heparin concentrations in children
ndergoing CPB (18,25,26,38). Despite this, anticoagula- mion management and monitoring during infant CPB con-
inue to be weight based (and derived from adult protocols),
nd the ACT is commonly used for pediatric patients
ndergoing cardiac surgery.
Even in adults, empirical protocols for CPB anticoagu-
ation have been shown to be suboptimal in reducing
emostatic activation (10). Individual heparin and prota-
ine management with patient-specific heparin concentra-
ions maintained during CPB is a more favorable method of
nticoagulation in adults and leads to improved clinical
utcomes (21,23).
Previously published studies in pediatric populations have also
emonstrated that individualized heparin concentration–based
rotocols for anticoagulation and protamine reversal appear
uperior to empirical weight-based protocols for infants and
hildren (18,20). In 1 study, the use of individualized
atient-specific heparin management in children resulted in
ositive results: less blood loss and fewer blood product
ransfusions. However, this study focused on older children,
ot on infants younger than 1 year of age (20). Guzzetta et
l (18) studied infants younger than 6 months of age (none
ounger than 1 month of age) undergoing elective repair of
congenital heart defect and compared weight-based hep-
rin dosing to individualized heparin management. They
howed significantly higher total heparin doses in the
reatment group compared with controls and greater sup-
ression of thrombin generation. There was, however, an
ncrease in 24-h chest tube drainage, which was not statis-
ically significant, and a higher blood product exposure in
he treatment group (18). Our data confirm these findings
ith a larger cohort of patients younger than 1 year of age
ncluding neonatal patients younger than 1 month of age. In
ddition, we have further elucidated some of the issues that
omplicate anticoagulation management during CPB in this
ery unique infant patient population, including the effect of
he immaturity of the coagulation system on anticoagulant
ensitivity, the influence of hemodilution on anticoagulation
onitoring, and the need for higher anticoagulant doses in
his population to limit overt inflammation and activation.
ur modification of the protocol resulted in lower blood
roduct exposure in the treatment group.
The benefits of using the HMS device for heparin and
rotamine management have been established in the adult
iterature. This study has uncovered certain limitations that
recondition its use in infants. The protocol described by
he manufacturer has been well investigated for use in
dults. However, it is clear that the device needs further
alidation for use in infants younger than 1 year of age based
n the results of the HMS I protocol. The device cannot be
afely used with the manufacturer’s suggested protocol.
Also, the cartridge used for detection of heparin reversal
s limited to a gross range of 0 to 0.4 U/ml heparin. We
ound that 47% of all patients in the treatment groups had
herapeutic laboratory plasma anti-Xa levels of 0.3 U/ml
t 5 min after protamine reversal despite a heparin prota-
ine titration measurement of 0 U/ml. Furthermore, 54%
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November 23, 2010:1794–802 Anticoagulation in Infant Heart Surgeryf patients in the control groups also demonstrated thera-
eutic anti-Xa levels after protamine reversal, indicating
hat full protamine reversal of the anti-Xa effects of heparin
as not achieved in approximately 50% of all patients.
levated anti-Xa levels were not widely observed on arrival
n the CCCU in any group. This may contribute to bleeding
n the immediate post-operative period when aggressive
lood component therapy is used to achieve hemostasis.
urther investigation of these findings is required to eluci-
ate the role of protamine and anti-Xa levels. Others have
emonstrated decreased post-operative blood losses when
educed protamine doses are used as well as increased
nti-Xa levels from the use of protamine itself (39).
Heparin management in the HMS I protocol was strictly
ollowed according to the heparin concentration recom-
ended by the heparin dose response calculated by the
MS device at induction. As a result, patients received
ignificantly more heparin and protamine in the treatment
roup that resulted in worse clinical outcomes including
ncreased chest tube volume losses, increased transfusion,
onger ventilation time, and longer CCCU and total hos-
ital length of stay. There were important observations
ade as a result of the HMS I clinical trial. The HMS
verestimated the amount of heparin required to achieve
dequate anticoagulation during CPB. The HMS may be
imited due to the programmed standard algorithms used to
alculate blood volume in this unique patient population in
hich blood and plasma volume is highly variable. The
mmaturity of the hemostatic system, cyanosis, congestive
eart failure, and the need for multiple surgical procedures
ay limit the accuracy of the calculation of the heparin
ose, predicting that higher levels of heparin are required to
btain optimal anticoagulation. Learning from the results in
he HMS I protocol, heparin management algorithms were
stablished for anesthesia loading and prime doses and
eparin concentration targets to be maintained while on
PB to maintain the equivalent plasma heparin concentra-
ion (anti-Xa) of 4.0 U/ml (25,26). This rationale for the
MS II protocol led us to set the whole blood heparin
anagement algorithm for all treatment patients at 3.0
/ml on the HMS device for the duration of CPB, thereby
till allowing for individualized patient management
hroughout each case. To maintain this heparin concentra-
ion throughout CPB, patients in the treatment group
eceived significantly more heparin than patients in the
ontrol group both at induction and throughout CPB,
hich resulted in significantly higher and more stable
aboratory anti-Xa levels.
onclusions
his prospective, randomized, controlled trial highlights the
mportance of evaluating equipment appropriately for dif-
erent patient populations. It also affirms the benefit of
chieving and maintaining adequate anticoagulation and
onitoring in patients younger than 1 year of age during
1PB. The use of the HMS device with a modified protocol
s a useful component of an anticoagulation strategy. This
tudy demonstrates that both low and very high levels of
eparin concentration lead to worse clinical outcomes.
dditional clinical studies that refine the appropriate pro-
amine dosing will complement these results.
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